- Home
- JYD vs CSBR Comparison
JYD vs CSBR Comparison
Compare JYD & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JYD
- CSBR
- Stock Information
- Founded
- JYD 2001
- CSBR 1985
- Country
- JYD China
- CSBR United States
- Employees
- JYD N/A
- CSBR N/A
- Industry
- JYD Oil Refining/Marketing
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JYD Consumer Discretionary
- CSBR Health Care
- Exchange
- JYD Nasdaq
- CSBR Nasdaq
- Market Cap
- JYD 87.4M
- CSBR 98.1M
- IPO Year
- JYD 2023
- CSBR 1986
- Fundamental
- Price
- JYD $1.99
- CSBR $7.55
- Analyst Decision
- JYD
- CSBR Strong Buy
- Analyst Count
- JYD 0
- CSBR 1
- Target Price
- JYD N/A
- CSBR $8.00
- AVG Volume (30 Days)
- JYD 3.1M
- CSBR 61.8K
- Earning Date
- JYD 01-03-2025
- CSBR 12-11-2024
- Dividend Yield
- JYD N/A
- CSBR N/A
- EPS Growth
- JYD N/A
- CSBR N/A
- EPS
- JYD N/A
- CSBR N/A
- Revenue
- JYD $82,427,232.00
- CSBR $53,571,000.00
- Revenue This Year
- JYD N/A
- CSBR $14.19
- Revenue Next Year
- JYD N/A
- CSBR $10.11
- P/E Ratio
- JYD N/A
- CSBR N/A
- Revenue Growth
- JYD 63.05
- CSBR 7.19
- 52 Week Low
- JYD $0.42
- CSBR $3.60
- 52 Week High
- JYD $2.83
- CSBR $7.85
- Technical
- Relative Strength Index (RSI)
- JYD 63.81
- CSBR 71.57
- Support Level
- JYD $1.69
- CSBR $4.61
- Resistance Level
- JYD $2.00
- CSBR $7.85
- Average True Range (ATR)
- JYD 0.38
- CSBR 0.75
- MACD
- JYD 0.02
- CSBR 0.26
- Stochastic Oscillator
- JYD 76.92
- CSBR 81.84
About JYD Jayud Global Logistics Limited
Jayud Global Logistics Ltd is a end-to-end supply chain solution providers in China, with a focus on providing cross-border logistics services. It offers freight forwarding services, (ii) supply chain management, and (iii) other value-added services.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.